| HP | Hypersensitivity Pneumonitis |
| HRCT | High-Resolution Computed Tomography |
| ILD | Interstitial Lung Disease |
| IPF | Idiopathic Pulmonary Fibrosis |
| PFT | Pulmonary Function Test |
| FVC | Forced Vital Capacity |
| DLCO | Diffusing Capacity of the Lung for Carbon Monoxide |
| BAL | Bronchoalveolar Lavage |
| EKG | Electrocardiogram |
| ANA | Anti-Nuclear-Antigen antibody panel |
| IgG | Immunoglobulin G |
| FEV | Forced Expiratory Volume |
| TLC | Total Lung Capacity |
| RV | Residual Volume |
| IgE | Immunoglobulin E |
| COPD | Chronic Obstructive Pulmonary Disease |
| ERV | Expiratory Reserve Volume |
| RB-ILD | Respiratory Bronchiolitis-Associated Interstitial Lung Disease |
| PaO2 | Partial Pressure of Oxygen |
| HE | Hematoxylin and Eosin |
| PaCO2 | Partial Pressure of Carbon Dioxide |
| PPF | Progressive Pulmonary Fibrosis |
| ABG | Arterial Blood Gas |
| MDD | Multidisciplinary discussion |
| ATS | American Thoracic Society |
| JRS | Japanese Respiratory Society |
| ALAT | Latin American Thoracic Association |
| Anti-nRNP/Sm | Anti-nuclear Ribonucleoprotein/Smith antibodies |
| Anti-Sm | Anti-Smith antibodies |
| Anti-SS-A (Ro) | Anti-SS-A (Ro) antibodies |
| Anti-Ro-52 | Anti-Ro-52 antibodies |
| Anti-SS-B (La) | Anti-SS-B (La) antibodies |
| Anti-Scl-70 | Anti-topoisomerase I (Scl-70) antibodies |
| Anti-PM-Scl 100 | Anti-PM-Scl 100 antibodies |
| Anti-Jo-1 | Anti-histidyl-tRNA synthetase (Jo-1) antibodies |
| Anti-Centromere B | Anti-centromere B antibodies |
| Anti-PCNA | Anti-proliferating cell nuclear antigen (PCNA) antibodies |
| Anti-dsDNA | Anti-double-stranded DNA antibodies |
| Anti-Nucleosome | Anti-nucleosome antibodies |
| Anti-Histone | Anti-histone antibodies |
| Anti-Ribosomal P Protein | Anti-ribosomal P protein antibodies |
| Anti-AMA-M2 | Anti-mitochondrial antibodies type M2 |
| Anti-DFS70 | Anti-dense fine speckled 70 antibodies |
| DIP | Desquamative Interstitial Pneumonia |
| SaO2 | Arterial Oxygen Saturation |
| HCO3− | Bicarbonate |
| MEF25 | Maximal Expiratory Flow at 25% of Forced Vital Capacity |